NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Visionaire becomes reality for Pfizer’s Array Bio $11 Bln acquisition:

NWBO CEO Linda Powers stated this Feb 2019 ASM:

Colo-rectal cancer is the number two cancer, second only to lung cancer. And if you’ve noticed in a lot of the publicity about immune-therapies, there’s been surprisingly little attention to colon cancer. If you also notice in the literature, checkpoint inhibitors, which are the big darlings of the pharma industry right now, have had no effect, none at all, in any patients with colo-rectal cancer except patients who have what’s called MSI, microsatellite instability a particular version of colon cancer, which only 5% of colon patients have. So we think that’s going to be a very interesting combination trial and we are looking forward to the day when we have enough resources and we can go forward with it.

And this is why PFE bought Array Bio:

The company is also testing its triple combo therapy in colorectal cancer patients.

"(The acquisition) sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Bourla said.

Pfizer bolsters cancer portfolio with $10.64 billion deal for Array - Reuters.com

Dr. Ashkan Europe’s PI in DCVAX L announced over a year ago he was transitioning towards Gene Therapy.

Roche bought Foundation Medicine(FMI) last year:

FMI develops tests to help doctors understand the genetic profile of patients' tumors and guide them to effective therapies.

Strategic Roadmap trump’s bits and pieces

DIFFERENT STROKES FOR DIFFERENT FOLKS